BioSpace News Archive

Stoke Therapeutics, Inc. announced positive safety, pharmacokinetic and cerebrospinal fluid exposure data from a planned interim analysis of the multi-center, open-label Phase 1/2a MONARCH study of STK-001 in children and adolescents with Dravet syndrome.

Statera Biopharma, Inc. will participate in the 2021 Cantor Virtual Global Healthcare Conference taking place September 27-30, 2001 .

Black Diamond Therapeutics and OpenEye Scientific announced that they are entering into a strategic partnership incorporating OpenEye’s Orion® molecular design platform into Black Diamond’s proprietary Mutation-Allostery-Pharmacology drug discovery engine to advance Black Diamond’s efforts to develop MasterKey inhibitor cancer therapies.

Small Pharma Inc. (TSXV: DMT) (the “Company” or “Small Pharma”), a neuropharmaceutical company focused on psychedelic-assisted therapies, today announced both the successful completion of the Phase I part of the combined Phase I/IIa clinical trial and the initiation of the Phase IIa part in combination with psychotherapy of its lead candidate, SPL026, for the treatment of Major Depressive Disorder (“MDD”).

Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company working to develop and launch the first FDA-approved ophthalmic formulation of bevacizumab for use in retinal indications, today announced that C. Russell Trenary, President and Chief Executive Officer of Outlook Therapeutics, will participate in a fireside chat hosted by Kristen Kluska, Director, Equity Research at the Cantor Fitzgerald Virtual Global Healthcare Conference

Intercept Pharmaceuticals, Inc. today announced that Jerry Durso, President and Chief Executive Officer of Intercept, M. Michelle Berrey, M.D., M.P.H., will present at the 2021 Cantor Virtual Global Healthcare Conference on Tuesday, September 28, 2021 at 8:40 a.m. ET.

Amolyt Pharma today announced that the company will present a poster at the American Society for Bone and Mineral Research 2021 Annual Meeting, October 1-4, 2021, in San Diego, CA.

Inari Medical, Inc. today announced that the company has appointed Victor F. Tapson, M.D. as VP of Medical Affairs.

-- Jorge Ruiz, M.D., Associate Director for Clinical Affairs, Geriatric Research at the Miami VA Healthcare System, will present Longeveron’s Aging Frailty Phase 2b Trial Data

Astellas Venture Management LLC (President: Kazunori Maruyama, Ph.D, “AVM”), a wholly-owned venture capital subsidiary of Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”), and Mission Bay Capital BioLabs (“MBC BioLabs”), a life-science incubator, today announced their third collaboration on the “Future Innovator Prize” formerly known as Astellas Golden Ticket.